# A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

> **NCT02915744** · PHASE3 · COMPLETED · sponsor: **Nektar Therapeutics** · enrollment: 178 (actual)

## Conditions studied

- Metastasis
- Breast Cancer

## Interventions

- **DRUG:** NKTR-102
- **DRUG:** Eribulin
- **DRUG:** Ixabepilone
- **DRUG:** Vinorelbine
- **DRUG:** Gemcitabine
- **DRUG:** Paclitaxel
- **DRUG:** Docetaxel
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT02915744
- **Lead sponsor:** Nektar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2020-07
- **Final completion:** 2020-07
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02915744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02915744, "A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT02915744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*